Read by QxMD icon Read

Pulmonary Circulation

Anne-Sophie Lacharite-Roberge, Farhan Raza, Riyaz Bashir, Chandra Dass, George Moser, William R Auger, Yoshiya Toyoda, Paul Forfia, Anjali Vaidya
No abstract text is available yet for this article.
September 11, 2018: Pulmonary Circulation
Daniela Vélez-Rendón, Xiaoyan Zhang, Jesse W Gerringer, Daniela Valdez-Jasso
No abstract text is available yet for this article.
September 3, 2018: Pulmonary Circulation
Wei Xiong, Mei Xu, Yunfeng Zhao, Bigyan Pudasaini, Fengfeng Han, Xuejun Guo, Jinming Liu
No abstract text is available yet for this article.
August 20, 2018: Pulmonary Circulation
Greta M Krafsur, Joseph Neary, Franklyn Garry, Holt Timothy, Daniel Gould, Gary Mason, Milton G Thomas, Mark R Enns, Rubin Tuder, Dale Brown, Kurt R Stenmark
No abstract text is available yet for this article.
August 20, 2018: Pulmonary Circulation
Rito Bergemann, James Allsopp, Harvey Jenner, Flora Ashley Daniels, Edmund Drage, Yevgeniy Samyshkin, Claude Schmitt, Steven Wood, David G Kiely, Allan Lawrie
Idiopathic pulmonary arterial hypertension (iPAH) is a rare progressive, life-shortening disease, usually diagnosed at an advanced stage. We hypothesize that patients with iPAH exhibit patterns of health-seeking behavior before diagnosis that will allow the development of earlier identification tools. The Sheffield Pulmonary Hypertension IndeX (SPHInX) project aims to develop a predictive algorithm based on routinely collected healthcare resource utilization (HCRU) data. This report focuses on the initial feasibility of the project, examining whether Hospital Episode Statistics (HES) data from the National Health Service in England have sufficient richness to support the development of an early diagnosis algorithm...
October 2018: Pulmonary Circulation
Yanan Cao, Zhenghua He, Maoen Zhu, Xiaowei Gao, Yue Yang, Junjie Zhang, Yundan Pan, Qulian Guo, Yonggang Peng, E Wang
Pulmonary fibrosis is often concomitant with myocardial injury. We studied sevoflurane's effects on cardiac function and the expression of the TLR4/inducible nitric oxide synthase (iNOS) signaling pathway on a pulmonary fibrosis model. C57BL/6J wild-type (WT) and TLR4-deficient (TLR4-/- ) mice were randomly divided into a control group and a pulmonary fibrosis group. The model of pulmonary fibrosis was induced by treatment with paraquat (PQ; 20 mg/kg). Four weeks after PQ administration, mice were tested for body weight changes, and histopathology and hydroxyproline in lung...
October 2018: Pulmonary Circulation
Alexi Crosby, Mark R Toshner, Mark R Southwood, Elaine Soon, Benjamin J Dunmore, Emily Groves, Stephen Moore, Penny Wright, Katrin Ottersbach, Cavan Bennett, Jose Guerrero, Cedric Ghevaert, Nicholas W Morrell
Increasing evidence suggests that patients with pulmonary arterial hypertension (PAH) demonstrate abnormalities in the bone marrow (BM) and hematopoietic progenitor cells. In addition, PAH is associated with myeloproliferative diseases. We have previously demonstrated that low-dose lipopolysaccharide (LPS) is a potent stimulus for the development of PAH in the context of a genetic PAH mouse model of BMPR2 dysfunction. We hypothesized that the hematopoietic progenitor cells might be driving disease in this model...
October 2018: Pulmonary Circulation
Stephen J Halliday, Meng Xu, Timothy E Thayer, Jonathan D Mosley, Quanhu Sheng, Fei Ye, Eric H Farber-Eger, Meredith E Pugh, Ivan R Robbins, Tufik R Assad, James D West, Evan L Brittain, Anna R Hemnes
Parenteral prostacyclin therapy is the most efficacious pharmacologic treatment for pulmonary arterial hypertension (PAH), but clinical response is variable. We sought to identify clinical, hemodynamic, and genetic associations with response to prostacyclin therapy. We performed a retrospective analysis of patients within a de-identified electronic health record and associated DNA biobank. Patients with PAH and a right heart catheterization (RHC) in the six months before initiation of a parenteral prostacyclin were included...
October 2018: Pulmonary Circulation
Andrew J Schissler, Robert J Gylnn, Piotr S Sobieszczyk, Aaron B Waxman
It is unclear if ultrasound-assisted catheter-directed thrombolysis (UACDT) confers benefit over anticoagulation (AC) alone in the management of intermediate-risk ("submassive") pulmonary embolism (PE), defined by evidence of right ventricular (RV) dysfunction in hemodynamically stable patients. This study sought to evaluate any lasting advantage of UACDT on mortality and resolution of RV dysfunction in intermediate-risk PE at a large academic medical center. Adults aged ≤ 86 years admitted with intermediate-risk PE from 2011 to 2016 were retrospectively identified...
October 2018: Pulmonary Circulation
Shin Watanabe, Kiyotake Ishikawa, Maria Plataki, Olympia Bikou, Erik Kohlbrenner, Jaume Aguero, Lahouaria Hadri, Iratxe Zarragoikoetxea, Kenneth Fish, Jane A Leopold, Roger J Hajjar
Nebulization delivery of adeno-associated virus serotype 1 encoding sarcoplasmic reticulum Ca2+ -ATPase2a (AAV1.SERCA2a) gene was examined in a Yukatan miniature swine model of chronic pulmonary hypertension (n = 13). Nebulization of AAV1.SERCA2a resulted in homogenous distribution of vectors, lower pulmonary vascular resistance, and a trend towards better long-term survival compared to control animals.
October 2018: Pulmonary Circulation
Manuel J Richter, Barbara Stollfuß, Alexander Roitenberg, Frank Kleinjung, Valentin Graeff, Sabine Berghaus, Christian Müller, Hossein-Ardeschir Ghofrani
Inhaled iloprost is an effective therapy for patients with pulmonary arterial hypertension (PAH); however, some patients experience extended inhalation times when using the V10 formulation (10.0 µg/mL) to deliver a 5 -µg dose (at mouthpiece) and are at risk of incomplete inhalations and reduced inhalation frequency. VENTASWITCH was an observational, case-crossover study to evaluate inhalation behavior in patients with PAH switched from iloprost V10 to V20 (20.0 µg/mL) formulation for delivering a 5 -µg dose using the I-Neb® AAD® device...
October 2018: Pulmonary Circulation
Chun Zhou, C Michael Francis, Ningyong Xu, Troy Stevens
The canonical transient receptor potential 4 (TRPC4) protein contributes to the molecular make-up of endothelial store-operated calcium entry channels. Store-operated calcium entry is a prominent mode of calcium influx in endothelium. Store-operated calcium entry channels are activated by inflammatory mediators and growth factors, and in endothelium, this process induces inter-endothelial cell gaps that increase permeability. Pulmonary endothelium within extra-alveolar segments, including pulmonary arteries, is especially sensitive to the activation of store-operated calcium entry...
October 2018: Pulmonary Circulation
Krishna R Patel, Christiana J Blair, James D Tislow
Treatment with endothelin receptor antagonists (ERA) can result in adverse hepatic effects in patients with pulmonary arterial hypertension (PAH). We evaluated the hepatic safety of ambrisentan (ABS), an ERA, used as monotherapy, or with tadalafil (TAD), a phosphodiesterase-5 (PDE5) inhibitor as initial combination therapy (ABS + TAD) in the AMBITION trial. This was a retrospective analysis set in academic and private outpatient clinics and research centers. This analysis included 596 patients with PAH who were randomized to ABS or TAD as monotherapy or ABS + TAD as initial combination therapy and received at least one dose of study drug, and who had baseline and follow-up hepatic function data...
October 2018: Pulmonary Circulation
Ya-Guo Zheng, Hong Ma, Liang Chen, Xiao-Min Jiang, Ling Zhou, Song Lin, Shao-Liang Chen
Oral targeted therapies play an important role in the treatment of pulmonary arterial hypertension (PAH). Several new oral agents have emerged for PAH in recent years. However, whether they provide a survival advantage is still not clear. This meta-analysis aimed to assess the efficacy and safety of oral targeted therapies, especially on predefined clinical worsening events. Trials were searched in the Cochrane Library, EMBASE, and PUBMED databases through June 2018. We calculated risk ratios for dichotomous data and weighted mean differences with 95% confidence intervals (CI) for continuous data...
October 2018: Pulmonary Circulation
Travis Maestas, Lillian M Hansen, Rebecca R Vanderpool, Ankit A Desai, Sophia Airhart, Shannon M Knapp, Adam Cohen, Jeremy Feldman, Franz P Rischard
Despite the increasing trends, reports on long-term follow-up are limited on transitioning from parenteral to oral treprostinil therapy in patients with pulmonary arterial hypertension (PAH). We investigated both the effectiveness of parenteral to oral treprostinil transition and the characteristics associated with transition failure over a duration of two years. The study included 37 Group I functional class I and II patients with PAH on combination therapy. Patients were excluded if cardiac index ≤2.2 L/min/m2 , right atrial pressure ≥11 mmHg, or 6-min walk distance ≤250 m...
October 2018: Pulmonary Circulation
Marylise Ginoux, Vincent Cottin, Jean-Charles Glérant, Julie Traclet, François Philit, Agathe Sénéchal, Jean-Francois Mornex, Ségolène Turquier
Right heart catheterization (RHC) is the reference test in diagnosing pulmonary hypertension (PH). The increasing age of patients at the time of diagnosis raises the issue of the morbidity of this invasive test in elderly individuals. We hypothesized that the morbidity associated with RHC would be increased in elderly patients and highlight differences in hemodynamic characteristics compared to younger patients. A retrospective study was conducted in a regional referral center for PH. Data for all consecutive RHCs performed during the study period were analyzed...
October 2018: Pulmonary Circulation
Debasree Banerjee, Sara E Vargas, Kate M Guthrie, Brittany M Wickham, Melissa Allahua, Mary E Whittenhall, Amy J Palmisciano, Corey E Ventetuolo
Pulmonary arterial hypertension (PAH) is characterized by progressive limitations in physical activity and health-related quality of life (HRQoL). HRQoL deficits may extend beyond the traditional domains of physical activity, psychological health, and emotional wellbeing to sexual health and function. Sexual HRQoL has not been studied in PAH, nor has the impact of PAH therapies themselves on sexual health and intimacy. In this initial investigation, we sought to explore HRQoL among women diagnosed with PAH and to determine if PAH treatment type (intravenous or subcutaneous prostanoids versus oral medications) was associated with levels of self-reported HRQoL assessed by validated measures for PAH-specific, general, and sexual HRQoL...
October 2018: Pulmonary Circulation
Veronique Atallah, Mathilde Meot, Manoelle Kossorotoff, Louise Galmiche-Rolland, Claude Lardeux, Benedicte Neven, Christine Bodemer, Damien Bonnet
Incontinentia pigmenti (IP) is a multisystemic disorder in which pulmonary arterial hypertension (PAH) is a severe and rarely reported association. The prognosis has been poor in reported cases. In our patient, IP was diagnosed during the neonatal period with a combination of cutaneous, ophthalmic, and neurological symptoms. The infant experienced severe collapse with bradycardia during general anesthesia to treat retinal telangiectasia. Echocardiography after resuscitation revealed suprasystemic pulmonary hypertension (PH)...
October 2018: Pulmonary Circulation
Nargues A Weir, Anna Conrey, Denise Lewis, Alem Mehari
Adults with sickle cell disease can develop pulmonary hypertension from a multitude of etiologies. Classified as WHO Group 5, there are no therapies approved for the treatment of sickle cell disease-pulmonary hypertension. Thromboembolic disease is prevalent in sickle cell disease and can lead to pulmonary hypertension. The only approved medical therapy for chronic thromboembolic pulmonary hypertension is riociguat. We report the experience, safety and tolerability of riociguat use in a series of sickle cell disease patients with chronic thromboembolic pulmonary hypertension...
October 2018: Pulmonary Circulation
Alessandra Greco, Sara Plumitallo, Laura Scelsi, Giannantonio Maggi, Matteo Sobrero, Annalisa Turco, Claudia Raineri, Natalia Arseni, Donata Cappelletti, Luigi Oltrona Visconti, Fabio Pagella, Giuseppe Spinozzi, Stefano Ghio, Carla Olivieri, Cesare Danesino
Hereditary hemorrhagic telangiectasia (HTT) is an autosomal dominant disease, most frequently caused by a mutation in either ENG or ACVRL1, which can be associated with pulmonary arterial hypertension (PAH). In this report, we describe a new unpublished ACVRL1 mutation segregating in three members of the same family, showing three different types of pulmonary hypertension (PH) in the absence of BMPR2 mutations. The first patient has a form of heritable PAH (HPAH) in the absence of hepatic arteriovenous malformations (AVMs); the second one has a severe form of portopulmonary hypertension (PoPAH) associated with multiple hepatic AVMs; the third one has hepatopulmonary syndrome (HPS) with numerous hepatic arteriovenous fistulas and a form of post-capillary PH due to high cardiac output...
October 2018: Pulmonary Circulation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"